Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
Novartis shares experienced a historic drop, falling 10 percent and clocking their worst trading day in over twenty years following a succession of three drug trial failures within a single week. The most recent blow involved an RNA drug failing to meet expectations in a rare muscle disease study, specifically impacting the late-stage DM1 study for the drug del-desiran. In response to these costly development setbacks, a major shareholder has demanded a comprehensive board overhaul and shake-up, turning investor attention sharply toward past mergers and acquisitions strategy.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Novartis shares plummeted 10 percent following three drug trial setbacks within a week.
- ✓ The latest trial failure involved the RNA drug del-desiran in a late-stage DM1 study for rare muscle disease.
- ✓ A major Novartis shareholder called for a board overhaul and shake-up following the costly deal and trial setbacks.
What changed
A major Novartis shareholder has demanded a board overhaul following a series of costly drug trial setbacks.
Live updates
-
Novartis Shares Plunge After Triple Drug Trial Setbacks
Novartis shares experienced a historic drop, falling 10 percent and clocking their worst trading day in over twenty years following a succession of three drug trial failures within a single week. The most recent blow involved an RNA drug failing to meet expectations in a rare muscle disease study, specifically impacting the late-stage DM1 study for the drug del-desiran. In response to these costly development setbacks, a major shareholder has demanded a comprehensive board overhaul and shake-up, turning investor attention sharply toward past mergers and acquisitions strategy.
Why it matters
The sudden cluster of three trial failures has dealt a severe blow to the pharmaceutical giant's pipeline confidence. These setbacks have also triggered sympathy declines for industry peers like DYN and SRPT. Disappointed investors are now intensely scrutinizing management decisions surrounding recent high-value corporate deals and asset acquisitions.
What is confirmed
- Novartis shares plummeted 10 percent following three drug trial setbacks within a week.
- The latest trial failure involved the RNA drug del-desiran in a late-stage DM1 study for rare muscle disease.
- A major Novartis shareholder called for a board overhaul and shake-up following the costly deal and trial setbacks.
What to watch next
- Any formal response from the Novartis board regarding the shareholder's call for an overhaul
- Further market reactions and stock performance updates for Novartis and peer companies like DYN and SRPT
confidence 100%Sources used for this update (11)
- CNBC — Pharma major Novartis plummets 10%, heading for worst day on record after three drug trial setbacks
- WSJ — Novartis’s Latest Trial Setback Sinks Stock
- Bloomberg.com — Novartis Sees Avidity Drug Fail in Third Setback in a Week
- Yahoo Finance — NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy
- BioPharma Dive — Novartis RNA drug falls short in rare muscle disease study
- Fierce Pharma — Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
- Reuters — EXCLUSIVE: Major Novartis shareholder calls for board shake-up after drug trial setbacks
- Yahoo Finance — Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
- Reuters — Novartis investors turn spotlight on M&A after trial setbacks
- FirstWord Pharma — Major shareholder calls for board change at Novartis: report
- BioSpace — Novartis drags peers down with triple asset stumble
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community